Research programme: thyroid hormone receptor beta agonists - Eccogene
Alternative Names: Liver targeting thyroid hormone receptor beta - Eccogene; THR-beta agonists - EccogeneLatest Information Update: 03 Sep 2021
At a glance
- Originator Eccogene
- Class Antihyperlipidaemics; Hepatoprotectants
- Mechanism of Action Thyroid hormone receptor beta agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Dyslipidaemias; Non-alcoholic steatohepatitis
Most Recent Events
- 30 Aug 2021 Thyroid hormone receptor beta agonists - Eccogene is available for licensing as of 30 Aug 2021. http://www.eccogene.com/pages_28/
- 30 Aug 2021 Preclinical trials in Dyslipidaemias in China (unspecified route) (Eccogene pipeline, August 2021)
- 30 Aug 2021 Preclinical trials in Non-alcoholic steatohepatitis in China (unspecified route) (Eccogene pipeline, August 2021)